Accendra Health, INC. (Formerly "owens & Minor, INC.")
Based in VA
AI Overview
With $4.3M in lobbying spend across 21 quarterly filings, Accendra Health, INC. (Formerly "owens & Minor, INC.") is a significant lobbying presence. Their lobbying covers 9 issue areas. Active from 2021 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2021 | $790K |
| 2022 | $980K |
| 2023 | $930K |
| 2024 | $800K |
| 2025 | $830K |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Accendra Health, INC. (Formerly "owens & Minor, INC.") disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Defense, Budget/Appropriations, Manufacturing, Veterans and 4 more
Legislative and regulatory proposals affecting the healthcare industry, including the manufacture and distribution of surgical and PPE products and the provision of solutions and expertise that suppor
Manufacture and distribution of medical/surgical PPE products and the provision of solutions and expertise that support critical patient care.
PPE supply chain and COVID-19.
Strategic National Stockpi
National Defense Authorization Act for Fiscal Year 2022: Manufacture and distribution of medical/surgical PPE products and the provision of solutions and expertise that support U.S. military efforts.
Appropriations for medical/surgical Personal Protective Equipment ("PPE"); United States Innovation and Competition Act of 2021 (S. 1260); Make PPE in America Act (H.R. 2720, S. 1306); Medical Supplie
Support for Domestic Manufacture and Sourcing of PPE; Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Governme
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.